Cotylenin A inhibits cell proliferation and induces apoptosis and PAX6 mRNA transcripts in retinoblastoma cell lines

Yoshiko Kashiwagi,1 Nobuo Kato,2 Takeshi Sassa,3 Koichi Nishitsuka,4 Teiko Yamamoto,1 Hiroshi Takamura,4 Hidetoshi Yamashita6

1Department of Ocular Cellular Engineering, Faculty of Medicine, Yamagata University, Yamagata City, Yamagata, Japan; 2The Institute of Scientific and Industrial Research, Osaka University, Ibaraki City, Osaka, Japan; 3Department of Bioresource Engineering, Faculty of Agriculture, Yamagata University, Tsuruoka City, Yamagata, Japan; 4Department of Ophthalmology and Visual Sciences, Faculty of Medicine, Yamagata University, Yamagata City, Yamagata, Japan

Purpose: Retinoblastoma, a childhood cancer of the retina, is caused by inactivation of the tumor suppressor gene retinoblastoma (RB). Cotylenin A (CN-A), a novel fuscoceane-diterpene glycoside, accelerates the differentiation of several types of myeloid cell lines and is a candidate for a new type of anticancer therapeutic agent with this effect. However, whether CN-A has the same effect on retinoblastoma cells is unknown. We studied the response of two retinoblastoma cell lines, Y-79 and WERI-Rb-1, to CN-A.

Methods: We studied the response of two retinoblastoma cell lines to CN-A with respect to cell growth, apoptosis, morphology, mRNA, protein expression analysis of specific genes (N-myc, cyclin-dependent kinase inhibitor 1A [P27], paired box gene 6 [PAX6], and rhodopsin [RHO]), and activity of three PAX6 promoters (P0, P1, and Pα).

Results: CN-A inhibited cell proliferation and induced apoptosis via caspase activity in the two retinoblastoma cell lines. In addition, CN-A induced mRNA expression of P21, PAX6, and RHO and protein expression of P21. In Y-79 cells, PAX6 P1 promoter was activated by CN-A. In WERI-Rb-1 cells, PAX6 P0, P1, and Pα promoter were activated by CN-A. CN-A decreased mRNA and protein expression of N-myc in two retinoblastoma cell lines.

Conclusions: The responses of retinoblastoma cells to CN-A include inhibition of cell growth, induction of apoptosis, and the potential to change neuroblastoma characteristics of retinoblastoma cells.

Retinoblastoma, a childhood cancer of the retina [1], is caused by an inheritable mutation of the tumor suppressor gene retinoblastoma (RB) [2]. Retinoblastoma has bipotential differentiation status and Müller- and photoreceptor-like characters [3]. Recently, the possibility that retinoblastoma results from a mixture of transformed retinal progenitor and transition cells was suggested [4]. Although the inactivation of the two RB alleles is the most important event in the oncogenesis of retinoblastoma, other oncogenes or tumor suppressor genes may also be involved in the aggressive progression of this tumor. Various therapies (e.g., chemotherapy, cryotherapy, thermotherapy, and radiation therapy) have been used to cure retinoblastoma [5].

Cotylenin A (CN-A), a novel fuscoceane-diterpene glycoside isolated from the culture filtrate of a fungus (Cladosporium sp.), is a plant growth regulator with cytokinin-like activity [6–8]. CN-A, which also has the ability to induce differentiation in several human and murine myeloid leukemia cell lines [9,10], significantly stimulated both functional and morphologic differentiation of leukemia cells in nine of 12 cases [11]. It has been reported that the ctrylenin A- induced differentiation of human leukemia cell lines is independent of the transforming growth factor-beta signaling system [12]. Combined treatment with interferon-α (IFN-α) and CN-A has induced apoptosis of human lung cancer cells [13]. In addition, this treatment has significantly inhibited the growth of both xenografted lung cancer cells, without apparent adverse side effects [13], and primary ovarian carcinoma cells [14]. Combined treatment with rapamycin and CN-A inhibited cell growth in breast carcinoma in vitro and in vivo [15]. Thus, CN-A is among the unique agents that accelerate cell differentiation [16]. Recently, CN-A was reported to be a molecule that binds to a 14–3–3 regulator protein complex [17]. However, whether CN-A has this effect on retinoblastoma cells is not known.

In this study, we examined the effect of CN-A on the proliferation and differentiation of human retinoblastoma cell lines Y-79 and WERI-Rb-1 (WERI) [18,19] to investigate whether retinoblastoma cells also respond to CN-A.

METHODS

Cell culture: Retinoblastoma cell lines Y-79 and WERI were obtained from the American Type Culture Collection (Manassas, VA). Y-79 and WERI cells were cultured on Roswell Park Memorial Institute (RPMI) 1640 medium (Invitrogen, Carlsbad, CA) containing 10% fetal bovine
Cotylenin A: CN-A was purified from the ethyl acetate extract of the culture filtrate of Cladosporium 501–7W [7,8]. CN-A was dissolved in dimethyl sulfoxide at 20-mg/ml concentration and then added to the medium at concentrations of 0, 10, or 20 μg/ml. Dimethyl sulfoxide at concentrations up to 0.1% had no effect on cell proliferation, gene expression, or morphology when added with or without CN-A.

**Assay of cell growth:** Cell Titer-Blue Assay (Promega, Madison, WI) was used to evaluate cell growth. Cells (1.0×10^4 cells/ml) were cultured with 0, 10, or 20 μg/ml CN-A for 0, 3, and 7 days in 96-well plates (CELLSTAR®; Greiner Bio-One, Frickenhausen, Germany). Then, 20 μl of the Cell Titer-Blue Assay solution was added, and the cells were incubated for 2 h at 37 °C and 5% CO_2_. Fluorescence (560/590 nm) was measured using a Gemini EM microplate spectrofluorometer (Molecular Devices, Sunnyvale, CA). The Mann–Whitney U-test (n=3) was used for statistical analysis.

**Terminal deoxynucleotidyl transferase (TdT) -mediated deoxyuridine 5′-triphosphate -biotin nick-end labeling assay (TUNEL) assay:** Cells (1.0×10^4 cells/ml) were incubated with or without 10 μg/ml CN-A for 7 days in six-well plates (CELLSTAR®). At the end of the treatment, the cells were washed with PBS (137 mM NaCl, 2.7 mM KCl, 10 mM Na_2HPO_4/KH_2PO_4, pH 7.4) and centrifuged for 5 min at 500× g for microscope slide cell preparations. We used the Apoptosis In Situ Detection Kit (Wako Pure Chemical Industries, Osaka, Japan) to evaluate cell apoptosis. Cells were fixed with 4% formalin neutral-buffered solution for 10 min. The 3′ terminals of DNA fragments, which in TUNEL positive cells was labeled by TdT protein, Peroxidase-conjugated TdT antibody and 3,3′-diaminobenzidine (DAB). The samples were covered with Soft Mounting Media (Wako Pure Chemical Industries, Osaka, Japan) electrophoresis and observed with a laser scanning microscope (LSM-510 Meta; Carl Zeiss MicroImaging, Thornwood, NY). Under the microscope, the total number of cells in 25 random fields per condition was counted: incidence=terminal transferase uridyl nick end labeling (TUNEL)-positive cells/all cells. The Mann–Whitney U-test (n=3) was used for statistical analysis.

**Observation of morphological changes and cell counting:** For morphological examination, cells were cultured in poly-D-lysine-coated tissue culture vessels (CELLSTAR®). Under the microscope, the total number of cells in ten random fields per condition was counted: dendrite-like process cells/all cells. The Mann–Whitney U-test (n=3) was used for statistical analysis.

**Reverse-transcriptase PCR analysis:** Total RNA was prepared by disrupting the cells in ISOGEN reagent (Nippon Gene, Toyama, Japan), and isopropanol precipitation. Total RNA (2 μg) was reverse transcribed with 200 U reverse transcriptase (Promega), 0.5 μg oligo (dT)16 primer, and 20 U RNase inhibitor (Takara Bio, Shiga, Japan) for 60 min. PCR amplifications were performed in 25-μl reaction mixtures containing 1.5 μl of the resulting cDNA, 200 μM deoxycytidine triphosphate (adenine, cytosine, guanine, and thymine) mixture (dNTP), 1 μM primers, and 1 U KOD® plus (Toyobo, Osaka, Japan). The resulting cDNAs were amplified using a KOD-Plus-PCR Kit (Toyobo) in 25 μl of medium. Primer sequences are detailed in Table 1. The PCR schedule was as follows: 1 min at 95 °C, followed by 20 (β-actin; ACTB) or 25–35 cycles, depending on the primer (other experiments); 15 s at 94 °C, 30 s at 60 °C or 55–65 °C, depending on the primer (other experiments); and a final extension step of 30 s at 68 °C and 1.5 min at 68 °C. Annealing temperatures and the number of PCR cycles are detailed in Table 1.

The PCR products were separated using 2% agarose gel (Iwai Chemicals, Tokyo, Japan) electrophoresis and visualized via ethidium bromide staining. Results were quantified using CS Analyzer software (ATTO Corporation, Tokyo, Japan).

**Western blot:** Cells (1.0×10^5 cells/ml) were incubated with or without 10 μg/ml CN-A for 5 days in six-well plates (CELLSTAR®). Cells were collected and lysed in sample buffer (50 mM Tris-HCl [pH 8.0], 150 mM NaCl, 1 mM EDTA, 1% Triton X-100, 0.1% sodium dodecyl sulfate [SDS], 0.1% sodium deoxycholate) with an added protease inhibitor cocktail (Roche Diagnostics, Basel, Switzerland) and 1 mM phenylmethylsulphonyl fluoride (Wako Pure Chemical Industries) at 4 °C. After sonication in ice water, crude lysates were cleared via centrifugation at 22,000× g for 30 min at 4 °C. The total protein concentration of the lysates was measured using the Bradford assay. Lysate aliquots were diluted at a 3:1 ratio with sample buffer (50 mM Tris-HCl [pH 6.8], 10% weight/volume [w/v] SDS, 10% v/v glycerol, 10% v/v 2-mercaptoethanol, 0.02% w/v bromophenol blue) and boiled 2 min. Equal amounts of protein (40–50 μg) were loaded onto 10% and 12.5% SDS-polyacrylamide gels and subjected to electrophoresis. The separated proteins were then electrotransferred to polyvinylidene fluoride (PVDF) membranes (Immun-Blot® PVDF membrane; Bio-Rad, Hercules, CA). Following electrotransfer, the blots were incubated for 60 min in a blocking solution (0.3% w/v dried low-fat milk/Tris-buffered saline) on an orbital shaker. The primary antibodies used in the blocking solution were anti-rhodopsin (antimouse; Sigma-Aldrich, St. Louis, MO); 1 μg/ml anti-PAX6 (antirabbit #PRB-278P, Covance, Princeton, NJ); anti-N-myc diluted 1:500 (antirabbit #9405; Cell Signaling Technology, Beverly, MA); anti-cleaved-poly (ADP-ribose) polymerase (PARP) diluted 1:500 (antirabbit #9541; Cell Signaling Technology); 1 μg/ml anti-cyclin-
| Gene              | Nucleotide (5′-3′)                                                                 | Accession number | Product (bp) | Annealing (°C)/cycles |
|-------------------|-----------------------------------------------------------------------------------|------------------|--------------|-----------------------|
| β-Actin           | F: CCCATGCCATCTGCGTCTG R: CGTCATACTCTGTGATGCTG                                      | NM_001101        | 573          | 60 °C/20 cycles       |
| PAX6              | F: ATGGTTTCTAATCGAGGG R: CGGTGTGGTGGGTTGGAAT                                       | NM_000280        | 149          | 58 °C/33 cycles       |
| RHO               | F: CATCGAGCGGTACGTGTTGGTGTTG          R: GCCGCAAGCATGGTGTTGAGC                 | NM_000539        | 577          | 65 °C/33 cycles       |
| P21               | F: CTCCAGAAGGAGCCCTAATCC R: TTTGATGATGCCCCCACTCG                                     | NM_000389        | 535          | 60 °C/25 cycles       |
| N-myc             | F: GACGACAAGGCCCCCTAGTAC R: GTGGAAGGAGGCACTGTT                                      | NM_005378        | 240          | 60 °C/25 cycles       |
| PAX6-P0 promoter  | F: GGTACCTTTCTATAGAGGGCAAGAC R: GCCTAGCTCCCAGTAACCTCGGTTTT                          | NG_008679        | 5315         | 60 °C/30 cycles       |
| PAX6-P1 promoter  | F: GGTACCTGCAAAAAAGAGAGAGCTTTGGGCG R: GCCTAGCCTTATAGAGGGCACTCCTCGG                  | NG_008679        | 3796         | 60 °C/30 cycles       |
| PAX6-Pa promoter  | F: GGTACCCAAGACGAGCATGCAAGACA R: GCCTAGCCTTTATAGAGGGCACTCCTCGG                        | NG_008679        | 3628         | 60 °C/30 cycles       |
| PAX6 (exon 11–13) | F: AACAGACACAGCCTTACAAAACA R: CGGGAACCTGAACTGGAAACTGAC                               | NM_000280        | 275          | 55 °C/35 cycles       |
| PAX6 (exon 3–6)   | F: GGAAGACTTTAATAGGGGC R: ATGGAGCCTGCACTCCGGCTT                                     | NM_000280        | 416          | 58 °C/33 cycles       |
dependent kinase inhibitor 1A (P21, #556430; BD Biosciences, San Jose, CA); anti-acetyl histone H3 diluted 1:1,000 (antirabbit #9671; Cell Signaling Technology); anti-acetyl histone H4 diluted 1:1,000 (antirabbit #2594; Cell Signaling Technology); 20 ng/ml anti-β-actin (antimouse #A5316; Sigma-Aldrich), and 1 μg/ml secondary horseradish peroxidase conjugate (mouse and rabbit; GE Healthcare, Little Chalfont, UK). The ECL™ Plus Western Blotting Detection System (GE Healthcare) was used for detection. Results were quantified using CS Analyzer software. The Mann–Whitney U-test (n=3) was used for statistical analysis.

**Promoter assay:** The pGL4.10-promoter vector was constructed using designed primers (Table 1) and the restriction enzymes KpnI and Nhe I. Cells were seeded in duplicate into 24-well plates (CELLSTAR®) at a density of 1×10^5 cells/well with growth medium. After 24 h, cells were transfected for 16 h with pGL4.10-promoter constructs and pGL4.74 plasmid (Promega) as an internal control for transfection efficiency using FuGENE HD (Roche Diagnostics). Luciferase activity in cells was measured using the Dual-Luciferase Reporter Assay System (Promega) with luminometer LB9507 (Berthold Technologies, Bad Wildbad, Germany). The Mann–Whitney U-test (n=3) was used for statistical analysis.

**RNA interference experiment:** A human PAX6-specific double-stranded small interfering (si)RNA was synthesized (Silencer Select Pre-Designed siRNA ID#s10067; Ambion, Austin, TX). A lipid transfection system (siPORT NeoFX transfection agent; Ambion) was used to introduce siRNAs into Y-79 and WERI cells via the following protocol: cells were preincubated with or without 10 μg/ml CN-A for 24 h, after which they were resuspended at a density of 10^5 cells/ml growth medium. One milliliter was seeded in duplicate into 24 wells (CELLSTAR®). The mixtures of siRNA and lipid reagent were added to 10^6 cells at a final concentration of 100 nM. Thereafter, cells were treated with or without 10 μg/ml CN-A for 48 h. Reverse transcriptase (RT)-PCR was conducted as described above.

**RESULTS**

**Cotylenin A inhibition of cell growth in two retinoblastoma cell lines:** To determine if CN-A inhibits cell growth, we investigated the cell viability of two retinoblastoma cell lines, Y-79 and WERI, in growth medium with 0, 10, and 20 μg/ml CN-A for 0, 3, and 7 days (Figure 1). At 10 and 20 μg/ml CN-A for 3 and 7 days, Y-79 and WERI cell growth decreased compared to control.

**Cotylenin A induction of apoptosis in two retinoblastoma cell lines:** CN-A has been reported to induce apoptosis in human lung carcinoma cells [13]. To investigate whether CN-A also induces apoptosis in a retinoblastoma cell line, we examined retinoblastoma cell lines cultured with or without 10 μg/ml CN-A for 7 days in noncoated tissue culture vessels using a TUNEL assay (Figure 2A,B) and western blot analysis (Figure 2C). CN-A treatment increased the number of TUNEL-positive cells threefold compared to untreated cells in the two cell lines (Figure 2B). Cleaved PARP can be used as a marker of the early stages of apoptosis because the PARP protein is cleaved by caspase-3 when apoptosis is induced [20,21], with nuclear condensation and fragmentation of chromosomal DNA occurring in the final stage of apoptosis.
Figure 2. Response of cotylenin A on cell death and apoptosis in retinoblastoma cell lines. A: Detection of apoptosis using a terminal deoxynucleotidyl transferase deoxyuridine 5'-triphosphate (dUTP) nick-end labeling (TUNEL) assay. Cells were treated with or without 10 μg/ml cotylenin A (CN-A) for 7 days. The bar represents 25 μm. The arrow points to TUNEL-positive cells. B: The bar graph indicates the percentage of TUNEL-positive cells. Asterisks indicate significant differences when compared with the control without CN-A (p<0.05); C) the bar graph and electrophoresis photographs indicate the protein expression of cleaved-Poly Adenosine diphosphate –ribose polymerase (PARP) in retinoblastoma cells. The bar graph indicates C-PARP protein expression (n=3); the error bar indicates the standard deviation. Asterisks indicate significant differences when compared with the control without CN-A (p<0.05).
Figure 3. Photographs of the morphology of retinoblastoma cell lines with and without cotylenin A. A: Photographs indicate morphology of retinoblastoma cells with or without 10 μg/ml CN-A for 2 days. The bars indicate the length of 25 μm. B: The graph indicates the percentage of the dendrite-like process cells (mean±SD, n=3). Asterisks indicate significant differences when compared with the control without CN-A (*p<0.05).
Figure 4. Expression of mRNA and protein in retinoblastoma cells. A: Some gene mRNA expression was investigated using reverse transcription polymerase chain reaction (RT–PCR). Cells were treated with or without 10 μg/ml cytolemin A (CN-A) for 3 days. The numbers (0, 10, and 20) indicate CN-A concentrations (μg/ml). β-Actin mRNA was used as an internal control.

B: Some protein expression was investigated using western blot analysis in retinoblastoma cells. Cells were treated with or without 10 μg/ml CN-A for 5 days. “Cont.” indicates the non-treatment. “CN-A” indicates the CN-A treatment (10 μg/ml). β-Tubulin protein was used as a loading control. C: The bar graph indicates the PAX6 protein expression (n=3); the error bar indicates the standard deviation.
Cleaved-PARP proteins in two retinoblastoma cell lines accumulated (Figure 2C).

Cotylenin A-induced morphological change in two retinoblastoma cell lines: To investigate whether CN-A caused morphological changes to retinoblastoma cells, we observed two retinoblastoma cell lines cultured with 10 μg/ml CN-A for 7 days in poly-D-lysine-coated tissue culture vessels (Figure 3) to allow adherence of the retinoblastoma cells, which are normally cultured in suspension. CN-A induced morphological changes in Y-79 and WERI cells, including the appearance of dendrite-like processes (Figure 3A, right). Figure 3B shows the percentage of the dendrite-like process cells at 0, 2, 4, 6, and 8 days with CN-A treatment. The percentage of the morphologically changed cells increased significantly by CN-A. At 2 days, the percentage was maximal for both Y-79 and WERI cells. The percentage of morphologically changed cells gradually declined at 4, 6, and 8 days.

Cotylenin A induced and decreased gene expression: We postulated that CN-A induced mRNA and protein expression of some genes in two retinoblastoma cell lines (Figure 4). N-myc has been reported to be expressed in retinoblastoma tumors and fetal retinas (but not adult retinas) [23] and to decrease during differentiation of neuroblastoma [24] and
retinoblastoma cell lines [25]. In Y-79 and WERI cells, CN-A reduced N-myc mRNA and protein expression. P21 has been reported to regulate cell-cycle progression at G1 [26]. In Y-79 and WERI cells, CN-A induced P21 mRNA and protein expression.

PAX6, a highly conserved transcription factor in vertebrates, is crucial for the development of the central nervous system, eye, nose, pancreas, and pituitary gland (reviewed in [27]). In Y-79 and WERI cells, CN-A induced PAX6 mRNA expression. In two cell lines, few increases of PAX6 protein expression were detected; however, significant increases of PAX6 protein were not detected at p<0.05 (Figure 4C).

RHO is a rod photoreceptor marker gene [28]. RHO expression increased in CN-A-treated Y-79 and WERI cells compared to untreated cells. In two cell lines, alternation of RHO protein expression was not detected.

Cotylenin A-induced PAX6 promoter activity in two cell lines: Three promoters of PAX6 (P0, P1, and Pu) have been identified (reviewed in [29]; Figure 5A). To confirm whether CN-A activates the PAX6 promoter, we investigated the luciferase activity of the promoters in two retinoblastoma cell lines after 48 h treatment with 10 μg/ml CN-A. In Y-79 and WERI cells, the P0 and P1 promoters were activated without CN-A treatment. With CN-A treatment the luciferase activity of only the PAX6 P1 promoters increased compared to that of the untreated control in Y-79 and WERI cells compared to untreated cells. In two cell lines, alternation of RHO protein expression was not detected.

Cotylenin A did not have the ability of a histone deacetylase inhibitor: Some differentiation agents have been known to exert histone deacetylase inhibitor activity (reviewed in [32]). In retinoblastoma cell lines, sodium butyrate has been reported to be the histone deacetylase inhibitor agent to have the ability of differentiation agents [33,34]. Therefore, we next examined cellular levels of acetylated histone H3 and H4 in the presence or absence of CN-A treatment. Western blot analysis showed that the accumulation of acetylated H3 and H4 in Y-79 and WERI cells were unchanged by CN-A treatment (Figure 8).

DISCUSSION

We showed that CN-A inhibits cell proliferation and induces cell death in two retinoblastoma cell lines (Figure 1 and Figure 2) as it does in other tumor cell lines [13–15,35]. Cleaved PARP western blot analysis results (Figure 2C) suggest that CN-A-induced apoptosis of retinoblastoma cells is caspase-dependent.
mediated. These results indicated that the response of retinoblastoma cells to CN-A is similar to that of other tumor cells [13,16].

CN-A induced Y-79 and WERI cells to exhibit dendrite-like processes (Figure 3, right), an effect similar to that of other differentiation reagents [25,33,36]. CN-A may dynamically change cell adhesion and cytoskeleton conformation of the retinoblastoma cell lines Y-79 and WERI cells. The elongation of CN-A induced-dendrite-like processes was not detected with continuous observation. In addition, the number of dendrite-like process cells gradually declined. With continuous observations, morphologically changed cells were found to die. Therefore, the morphological change by CN-A may be related to CN-A-induced apoptosis.

CN-A reduced the expression of the oncogene N-myc, a neuroblastoma marker that has been reported to be expressed in retinoblastoma tumors and fetal retinas (but not adult retinas) [23], and to decrease during the differentiation of neuroblastoma [24] and retinoblastoma cell lines [25]. This suggests that the neurtumor state of retinoblastoma cell lines changes by CN-A.

CN-A increased the mRNA and protein expression of P21 in Y-79 and WERI cells (Figure 4A,B). P21 protein has been reported to regulate cell-cycle progression at G1 [26]. In Y-79 and WERI cells, CN-A is considered to induce not only apoptosis but also cell-cycle inhibition.

CN-A increased the mRNA expression of PAX6 in Y79 and WERI cells (Figure 4A). PAX6 has been reported to play multiple roles in both lens and retinal development [37] and is required for the proliferation and expansion of retinal stem cells [38]. Three promoters of PAX6 (P0, P1, and Pa) have been identified (reviewed in [29]; Figure 5A). In addition, PAX6 has three isoforms: normal PAX6, PAX6 (5a), and paired domain-less (ΔPD)PAX6. The P0 and P1 promoter transcripts have been reported to encode normal PAX6 and PAX6 (5a) splice variants. It has been reported that (ΔPD)PAX6 mRNA is transcribed by activation of the Pa promoter [30,31]. CN-A-induced PAX6 splice variant mRNA expression patterns also differed between the two retinoblastoma cell lines, corresponding to activation of three PAX6 promoters by CN-A (Figure 6). Normal PAX6 mRNA translated into a 47-kDa protein with 422 amino acids. The
mass of the deduced amino acid of Δexon5 PAX6 mRNA was about 32 kDa and contained 286 amino acids. It is presumed that the deduced amino acid of Δexon5 PAX6 is (ΔPD)-PAX6 proteins [29]. Δexon5 PAX6 mRNA expression in WERI was considered to be transcribed by PAX6 Pu promoter activity. A western blot investigation on the expression of the Δexon5 PAX6 protein induced by CN-A in WERI cells showed that the mass of the deduced amino acid of Δexon5 PAX6 mRNA was not detected with or without CN-A-treatment (data not shown). Overexpression of (ΔPD)-PAX6 causes a severe microphthalmic phenotype due to apoptotic cell death in the lens during embryonic development [31,37]. Little is known about the molecular mechanism and function of (ΔPD)-PAX6. We attempted to overexpress the Δexon5 PAX6 mRNA in WERI cells; however, RHO gene expression change was not detected (data not shown). The (ΔPD)-PAX6 mRNA expression in WERI cells by CN-A may be related to apoptosis or another cell physiology. The different response to CN-A on PAX6 transcription in two retinoblastoma cell lines is unique. CN-A may be useful in researching the expression of PAX6 splice variants.

RHO is a rod photoreceptor marker gene [28] that is modulated by PAX6 in Drosophila [39]. In Y-79 and WERI cells, CN-A induced RHO mRNA expression (Figure 4A) but it did not induce RHO protein expression (Figure 4B). In the PAX6 siRNA experiment in Y-79 and WERI cells with CN-A treatment, the expression pattern of PAX6 mRNA was similar to that of RHO mRNA (Figure 7). These results indicate that PAX6 mRNA expression may participate in the expression of RHO. CN-A-induced PAX6 is considered to modulate the expression of RHO mRNA. In addition, CN-A may induce rod photoreceptor differentiation in retinoblastoma cell lines.

The reagents that promote the differentiation of retinoblastoma cell lines include retinoic acid (RA)-induced cone photoreceptor-specific genes in WERI cells [35]. RA has been used in combination with other reagents to induce photoreceptor differentiation of embryonic stem cells [40]. Butyrate has been reported to induced Recoverin, the rod photoreceptor marker gene, mRNA, and protein in Y-79 cells [41] and dibutyryl cyclic adenosine 3′, 5′-monophosphate (AMP) and butyrate-induced morphological changes in Y-79 cells [25,33]. In particular, butyrate has been reported to be a histone deacetylase inhibitor agent [32,33]. However, CN-A does not have the ability to inhibit histone deacetylation. Treatment with a combination of CN-A and vitamin D3 is reported to be more effective than treatment with CN-A or vitamin D3 alone in inducing the differentiation of acute monocytic leukemia cells [42]. The effect of CN-A appears to involve a more diverse array of factors compared to other differentiation-inducing reagents. These previous reports have indicated that the effects of CN-A in retinoblastoma cell lines can be extrapolated to other cytokines or differentiation-inducing reagents, including RA, butyrate, and dibutyryl cyclic AMP.

In summary, we found that CN-A is a potent inhibitor of cell proliferation and apoptosis, and it changes tumor characteristics in retinoblastoma cell lines. Differences in the effect of CN-A on ocular retinoblastoma tumors and metastatic tumors were observed. CN-A may be useful in researching PAX6 splice variants. The effect of CN-A on retinoblastoma cells indicates that CN-A may have distinct functions beyond what we have reported here. Further work is required to elucidate the mechanisms underlying these novel observations.

**ACKNOWLEDGMENTS**

This work was supported by a grant from Senju Pharmaceutical Co., Ltd. The authors thank Motoko Inomata and Kuniko Horie (Saitama University Faculty of Medicine) for provide cell lines. This study supported by Grant-in-Aid from Japan Society for the Promotion of Science. This research was supported by a Grant-in-Aid from the Ministry of Education, Culture, Sports, Science, and Technology of Japan.
REFERENCES

1. Albert DM. Historic review of retinoblastoma. Ophthalmology 1987; 94:654-62. [PMID: 3306547]

2. Lueder GT, Smith ME. Retinoblastoma. Semin Diagn Pathol 1994; 11:104-6. [PMID: 7809503]

3. Nork TM, Schwartz TL, Doshi HM, Millecchia LL. Retinoblastoma: cell of origin. Arch Ophthalmol 1995; 113:791-802. [PMID: 7786223]

4. Dyer MA, Bremner R. The search for the retinoblastoma cell of origin. Nat Rev Cancer 2005; 5:91-101. [PMID: 15685194]

5. Rodriguez-Galindo C, Wilson MW, Chantada G, Fu L, Qaddoumi I, Antoneli C, Leal-Leal C, Sharma T, Barnoya M, Epelman S, Pizzarello L, Kane JR, Barfield R, Merchant TE, Robison LL, Murphree AL, Chevez-Barrios P, Dyer MA, O’Brien J, Ribeiro RC, Hungerford J, Helveston EM, Haik BG, Wilimas J. Retinoblastoma: one world, one vision. Pediatrics 2008; 122:e763-70. [PMID: 18762512]

6. Sassa T, Tojyo T, Munakata K. Isolation of a new plant growth regulator. Br J Haematol 2001; 112:697-705. [PMID: 11260075]

7. Sassa T, Togashi M, Kitaguchi T. The structures of cotylenins A, B, C, D, and E. Agric Biol Chem 1975; 39:1735-44.

8. Sassa T, Ooi T, Nukina M, Ikeda M, Kato N. Structural confirmation of cotylenin A, a novel fusicoccane-diterpene glycoside with potent plant growth-regulating activity from Cladosporium fungus sp. 501–07W. Biosci Biotechnol Biochem 1998; 62:1815-8.

9. Asahi K, Honma Y, Hazeki K, Sassa T, Kubohara Y, Sakurai A, Takahashi N, Cotylenin A. a differentiation-inducing agent, and IFN-alpha cooperatively induce apoptosis and have an antitumor effect on human non-small cell lung carcinoma cells in nude mice. Cancer Res 2003; 63:3659-66. [PMID: 12839956]

10. Honma Y, Cotylenin A. a plant growth regulator as a differentiation-inducing agent and a mammalian homolog of CED-3, is a CrmA-inhibitable protease that cleaves the death substrate poly(ADP-ribose) polymerase. Cell 1995; 81:801-9. [PMID: 7774019]

11. Nicholson DW, Ali A, Thornberry NA, Vaillancourt JP, Ding CK, Gallant M, Gareau Y, Griffin PR, Labelle M, Lazebnik YA. Identification and inhibition of the ICE/CED-3 protease necessary for mammalian apoptosis. Nature 1995; 376:37-43. [PMID: 7596430]

12. Arends MJ, Morris RG, Wylie AH. Apoptosis. The role of the endonuclease. Am J Pathol 1990; 136:593-608. [PMID: 2156431]

13. Squire J, Goddard AD, Canton M, Becker A, Phillips RA, Gallie BL. Tumour induction by the retinoblastoma mutation is independent of N-myc expression. Nature 1986; 322:555-7. [PMID: 2426601]

14. Murakami T, Ohmori H, Gotoh S, Tsuda T, Ohya R, Akiya S, Higashi K. Down modulation of N-myc, heat-shock protein 70, and nucleolin during the differentiation of human neuroblastoma cells. J Biochem 1991; 110:146-50. [PMID: 1657899]

15. Murakami T, Takahashi H, Akiya S, Higashi K. Effects of dibutyryl cyclic AMP on the gene expression during the differentiation of retinoblastoma cells (Y 79) in culture. Nippon Ganka Gakkai Zasshi 1993; 97:703-7. [PMID: 8392280]

16. Honma Y, Akimoto M. Therapeutic strategy using phenotypic modulation of cancer cells by differentiation-inducing agents. Cancer Sci 2007; 98:1643-51. [PMID: 17645578]

17. Asahi K, Honma Y, Hazeki K, Sassa T, Kubohara Y, Sakurai A, Takahashi N, Cotylenin A. a plant-growth regulator, induces the differentiation in murine and human myeloid leukemia cells. Biochem Biophys Res Commun 1997; 238:758-63. [PMID: 9325163]

18. Reid TW, Albert DM, Rabson AS, Russell P, Craft J, Chu EW, Tralka TS, Wilcox JL. Characteristics of an established cell line of retinoblastoma. J Natl Cancer Inst 1974; 53:347-60. [PMID: 4135597]

19. McFall RC, Sery TW, Makadon M. Characterization of a new continuous cell line derived from a human retinoblastoma. Cancer Res 1977; 37:1003-10. [PMID: 844036]

20. Tewari M, Quan LT, O’Rourke K, Desnoyers S, Zeng Z, Beidler DR, Poirier GG, Salvesen GS, Dxit VX. Yama/CPP32 beta, a mammalian homolog of CED-3, is a CrmA-inhibitable protease that cleaves the death substrate poly(ADP-ribose) polymerase. Cell 1995; 81:801-9. [PMID: 7774019]

21. Xiaomei D, Yu H, Tang X, Yuan J, Niu L, Du X, Wang M, Li Q, Teng Y, Yang L, Sun H. Identification and characterization of a new gene, LOC727520, that is upregulated in retinoblastoma cells. Cancer Res 2005; 65:4363-70. [PMID: 15986633]

22. Chen X, Li J, Yang J, Liu X, Wu Y, Sun B, Zhang L, Li T, Li Y, Cui H, Li Y. Identification and characterization of a novel gene, LOC727520, that is upregulated in retinoblastoma cells. Cancer Res 2005; 65:4363-70. [PMID: 15986633]
homeodomain in brain development. Development 2004; 131:6131-40. [PMID: 15548580]

30. Kammandel B, Chowdhury K, Stoykova A, Aparicio S, Brenner S, Gruss P. Distinct cis-essential modules direct the time-space pattern of the Pax6 gene activity. Dev Biol 1999; 205:79-97. [PMID: 9882499]

31. Kim J, Lauderdale JD. Analysis of Pax6 expression using a BAC transgene reveals the presence of a paired-less isoform of Pax6 in the eye and olfactory bulb. Dev Biol 2006; 292:486-505. [PMID: 16464444]

32. Botrugno OA, Santoro F, Minucci S. Histone deacetylase inhibitors as a new weapon in the arsenal of differentiation therapies of cancer. Cancer Lett 2008; 280:134-44.

33. Karasawa Y, Okisaka S. Inhibition of histone deacetylation by butyrate induces morphological changes in Y79 retinoblastoma cells. Jpn J Ophthalmol 2004; 48:542-51. [PMID: 15592778]

34. Tsokos M, Kyriasis AP, Chader GJ, Triche TJ. Differentiation of human retinoblastoma in vitro into cell types with characteristics observed in embryonal or mature retina. Am J Pathol 1986; 123:542-52. [PMID: 3013012]

35. Kasukabe T, Okabe-Kado J, Honma Y, Cotylenin A. a new differentiation inducer, and rapamycin cooperatively inhibit growth of cancer cells through induction of cyclin G2. Cancer Sci 2008; 99:1693-8. [PMID: 18754885]

36. Li A, Zhu X, Brown B, Craft CM. Gene expression networks underlying retinoic acid-induced differentiation of human retinoblastoma cells. Invest Ophthalmol Vis Sci 2003; 44:996-1007. [PMID: 12601020]

37. Kim J, Lauderdale JD. Overexpression of pairedless Pax6 in the retina disrupts corneal development and affects lens cell survival. Dev Biol 2008; 313:434-54. [PMID: 18062951]

38. Xu S, Sunderland ME, Coles BL, Kam A, Holowacz T, Ashery-Padon R, Marquardt T, McInnes RR, van der Kooy D. The proliferation and expansion of retinal stem cells require functional Pax6. Dev Biol 2007; 304:713-21. [PMID: 17316600]

39. Sheng G, Thouvenot E, Schmucker D, Wilson DS, Desplan C. Direct regulation of rhodopsin 1 by Pax-6/eyeless in Drosophila: evidence for a conserved function in photoreceptors. Genes Dev 1997; 11:1122-31. [PMID: 9159393]

40. Ikeda H, Osakada F, Watanabe K, Mizuseki K, Haraguchi T, Miyoshi H, Kamiya D, Honda Y, Sasai N, Yoshimura N, Takahashi M, Sasai Y. Generation of Rx+/Pax6+ neural retinal precursors from embryonic stem cells. Proc Natl Acad Sci USA 2005; 102:11331-6. [PMID: 16076961]

41. Wiechmann AF. Recoverin in cultured human retinoblastoma cells: enhanced expression during morphological differentiation. J Neurochem 1996; 67:105-10. [PMID: 8666979]

42. Yamada K, Honma Y, Asahi KI, Sassa T, Hino KI, Tomoyasu S. Differentiation of human acute myeloid leukaemia cells in primary culture in response to cotylenin A, a plant growth regulator. Br J Haematol 2001; 114:814-21. [PMID: 11564068]